CW Advisors LLC Buys Shares of 5,720 Insmed, Inc. $INSM

CW Advisors LLC purchased a new position in Insmed, Inc. (NASDAQ:INSM) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,720 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

Several other institutional investors have also made changes to their positions in the stock. Norges Bank acquired a new position in Insmed in the 2nd quarter valued at approximately $194,728,000. Adage Capital Partners GP L.L.C. increased its stake in shares of Insmed by 109.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after acquiring an additional 1,799,382 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Insmed during the first quarter worth $88,351,000. 1832 Asset Management L.P. acquired a new stake in Insmed during the first quarter valued at $37,214,000. Finally, Wellington Management Group LLP boosted its position in Insmed by 62.5% during the first quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company’s stock valued at $93,274,000 after purchasing an additional 470,401 shares during the last quarter.

Insmed Stock Down 1.2%

INSM stock opened at $194.17 on Wednesday. The stock has a market capitalization of $41.41 billion, a price-to-earnings ratio of -31.37 and a beta of 1.01. The company has a 50-day moving average of $182.60 and a two-hundred day moving average of $137.24. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same period in the prior year, the firm posted ($1.27) EPS. Insmed’s revenue for the quarter was up 52.4% on a year-over-year basis. As a group, equities research analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling

In other news, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the sale, the director owned 262,675 shares in the company, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the transaction, the insider owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. The trade was a 33.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 233,650 shares of company stock valued at $41,063,785 in the last ninety days. Company insiders own 3.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald started coverage on Insmed in a research note on Tuesday, October 28th. They set an “overweight” rating and a $192.00 price target for the company. JPMorgan Chase & Co. raised their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 20th. UBS Group boosted their target price on shares of Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Evercore ISI restated an “outperform” rating and set a $180.00 price target on shares of Insmed in a report on Wednesday, October 1st. Finally, Rothschild Redb upgraded shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $187.89.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.